{"url_path":"/sec/fblg/8-k/2026-06-23/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-279778-index.html","accession_number":"0001193125-26-279778","cik":"0001958777","ticker":"FBLG","issuer_name":"FibroBiologics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-279778-index.html","primary_entity_key":"0001958777","primary_entity_name":"FibroBiologics, Inc."},"word_count":84,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n[Exhibit 10.1](fblg-ex10_1.htm)\n\n \n\n[FibroBiologics, Inc. 2026 Equity and Incentive Compensation Plan](fblg-ex10_1.htm)\n\n[Exhibit 10.2](fblg-ex10_2.htm)\n\n \n\n[Form of Stock Option Agreement](fblg-ex10_2.htm)\n\nExhibit 104\n\nCover Page Interactive Data File (embedded within the inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nFibroBiologics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 23, 2026\n\nBy:\n\n/s/ Pete O'Heeron\n\n \n\n \n\n \n\nName: Pete O'Heeron\nTitle: Chief Executive Officer"}